Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

ClinicalTrials.gov ID: NCT03422653

Public ClinicalTrials.gov record NCT03422653. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus, With a 52-Week Open Label Extension

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes a 12-week Double-blind Phase and a 52-week Open-label Extension Phase.

Study identification

NCT ID
NCT03422653
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Cara Therapeutics, Inc.
Industry
Enrollment
378 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 19, 2018
Primary completion
Apr 5, 2019
Completion
Mar 25, 2020
Last update posted
Apr 25, 2022

2018 – 2020

United States locations

U.S. sites
57
U.S. states
20
U.S. cities
55
Facility City State ZIP Site status
Cara Therapeutics Study Site Homewood Alabama 35209
Cara Therapeutics Study Site Huntsville Alabama 35805
Cara Therapeutics Study Site Bakersfield California 93309-5030
Cara Therapeutics Study Site 2 Beverly Hills California 90211
Cara Therapeutics Study Site Beverly Hills California 90211
Cara Therapeutics Study Site Chula Vista California 91910
Cara Therapeutics Study Site Corona California 92881
Cara Therapeutics Study Site Escondido California 92025
Cara Therapeutics Study Site Fountain Valley California 92708
Cara Therapeutics La Mesa California 91942
Cara Therapeutics Study Site Long Beach California 90807
Cara Therapeutics Study Site Ontario California 91762
Cara Therapeutics Study Site Riverside California 92505
Cara Therapeutics Study Site Roseville California 95661
Cara Therapeutics Study Site San Diego California 92111
Cara Therapeutics Study Site San Dimas California 91773
Cara Therapeutics Study Site Tarzana California 91356
Cara Therapeutics Study Site Denver Colorado 80218
Cara Therapeutics Study Site Bridgeport Connecticut 06606
Cara Therapeutics Study Site Hartford Connecticut 06112
Cara Therapeutics Study Site Middlebury Connecticut 06762
Cara Therapeutics Study Site 1 Coral Springs Florida 33071
Cara Therapeutics Study Site Hialeah Florida 33016
Cara Therapeutics Study Site Miami Florida 33125
Cara Therapeutics Study Site Miami Gardens Florida 33169
Cara Therapeutics Study Site Tampa Florida 33614
Cara Therapeutics Study Site Kalamazoo Michigan 49007
Cara Therapeutics Study Site Roseville Michigan 48066
Cara Therapeutics Study Site Minneapolis Minnesota 55404
Cara Therapeutics Study Site Brookhaven Mississippi 39601
Cara Therapeutics Study Site McComb Mississippi 39648
Cara Therapeutics Study Site Tupelo Mississippi 38801
Cara Therapeutics Study Site Kansas City Missouri 64111
Cara Therapeutics Study Site Las Vegas Nevada 89102
Cara Therapeutics Study Site Las Vegas Nevada 89106
Cara Therapeutics Study Site Eatontown New Jersey 07724
Cara Therapeutics Study Site Albuquerque New Mexico 87109
Cara Therapeutics Study Site Gallup New Mexico 87301
Cara Therapeutics Study Site Fresh Meadows New York 11365
Cara Therapeutics Study Site Great Neck New York 11021
Cara Therapeutics Study Site The Bronx New York 10461
Cara Therapeutics Study Site Durham North Carolina 27704
Cara Therapeutics Study Site Canton Ohio 44718
Cara Therapeutics Study Site Roseburg Oregon 97471
Cara Therapeutics Study Site Chattanooga Tennessee 37408
Cara Therapeutics Study Site Dallas Texas 75231
Cara Therapeutics Study Site Duncanville Texas 75137
Cara Therapeutics Study Site Greenville Texas 75402
Cara Therapeutics Study Site Houston Texas 77054
Cara Therapeutics Study Site Lewisville Texas 75057
Cara Therapeutics Study Site McAllen Texas 78503
Cara Therapeutics Study Site Mesquite Texas 75150
Cara Therapeutics Study Site San Antonio Texas 78207
Cara Therapeutics Study Site Waxahachie Texas 75165
Cara Therapeutics Study Site Chesapeake Virginia 23320
Cara Therapeutics Study Site Hampton Virginia 23666
Cara Therapeutics Study Site Wauwatosa Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03422653, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 25, 2022 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03422653 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →